title: Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion.
abstract: Age-related degeneration of basal forebrain cholinergic neurons (BFCNs) contributes to cognitive decline in Alzheimer's disease and Down's syndrome. With aging, the partial trisomy 16 (Ts65Dn) mouse model of Down's syndrome exhibited reductions in BFCN size and number and regressive changes in the hippocampal terminal fields of these neurons with respect to diploid controls. The changes were associated with significantly impaired retrograde transport of nerve growth factor (NGF) from the hippocampus to the basal forebrain. Intracerebroventricular NGF infusion reversed well established abnormalities in BFCN size and number and restored the deficit in cholinergic innervation. The findings are evidence that even BFCNs chronically deprived of endogenous NGF respond to an intervention that compensates for defective retrograde transport. We suggest that age-related cholinergic neurodegeneration may be a treatable disorder of failed retrograde NGF signaling.
authors.affiliation: Department of Neurology and Neurological Sciences and the Program in Neuroscience, Stanford University, Stanford, CA 94305, USA. j.cooper@iop.kcl.ac.uk
authors.forename: J D
authors.initials: JD
authors.lastname: Cooper
authors.forename: A
authors.initials: A
authors.lastname: Salehi
authors.forename: J D
authors.initials: JD
authors.lastname: Delcroix
authors.forename: C L
authors.initials: CL
authors.lastname: Howe
authors.forename: P V
authors.initials: PV
authors.lastname: Belichenko
authors.forename: J
authors.initials: J
authors.lastname: Chua-Couzens
authors.forename: J F
authors.initials: JF
authors.lastname: Kilbridge
authors.forename: E J
authors.initials: EJ
authors.lastname: Carlson
authors.forename: C J
authors.initials: CJ
authors.lastname: Epstein
authors.forename: W C
authors.initials: WC
authors.lastname: Mobley
mesh_terms: D000375:Aging / Q000378:metabolism / Q000473:pathology; D000818:Animals; D001693:Biological Transport, Active; D002452:Cell Count; D002477:Cells; D002799:Cholinergic Fibers / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D004314:Down Syndrome / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D006624:Hippocampus / Q000378:metabolism; D006801:Humans; D007263:Infusions, Parenteral; D051379:Mice; D008817:Mice, Mutant Strains; D009410:Nerve Degeneration / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D020932:Nerve Growth Factor / Q000008:administration & dosage / Q000378:metabolism*; D010641:Phenotype; D016548:Prosencephalon / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D014314:Trisomy
chemical_list: D020932:Nerve Growth Factor